Johnson & Johnson

NYSE:JNJ   12:11:05 PM EDT
163.63
-2.12 (-1.28%)
Products

U.S. FDA Publishes Briefing Documents Ahead Of Meeting On J&J's COVID-19 Vaccine Booster

Published: 10/13/2021 14:20 GMT
Johnson & Johnson (JNJ) - :u.s. FDA Publishes Briefing Documents on Request for a Booster Dose of the Johnson & Johnson Covid-19 Vaccine.
FDA Advisory Panel on Oct 15 to Discuss Whether Data Submitted by Johnson & Johnson Supports a Booster Dose at Least 2 Months After Original Dose.
FDA Advisory Panel to Discuss If J&j's Data Supports That a Gap of at Least 6 Months Between Booster and Original Dose May Result in More Robust Response.
FDA, in Briefing Documents, Says Unable to Conduct Independent Review to Verify Analyses Submitted by J&j to Support Use of Covid-19 Vaccine Booster Dose.
FDA Says It Relied on J&j's Analyses of Booster Dose Data As It Did Not Have Time to Independently Assess the Analyses.
Further Company Coverage: Jnjn ((reuters.
Briefs@thomsonreuters.
Com;)).